Managing Cardiotoxicity of Chemotherapy

Current Treatment Options in Cardiovascular Medicine

Volumn 15, Issue 4, 2013, Pages 410-424

  Colombo, Alessandro ^a   Meroni, Carlo A ^a   Cipolla, Carlo M ^a   Cardinale, Daniela ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Angiotensin converting enzyme inhibitors; Anthracycline; Beta blockers; Biomarkers; Cancer therapy; Cardiotoxicity; Left ventricular dysfunction; Prevention; Trastuzumab; Treatment; Troponin

Indexed keywords

ANTHRACYCLINE; ANTIOXIDANT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEVACIZUMAB; CAPECITABINE; CARVEDILOL; CISPLATIN; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXORUBICIN; EPIRUBICIN; FLUINDOSTATIN; FLUOROURACIL; IMATINIB; LAPATINIB; MITOXANTRONE; NEBIVOLOL; NILOTINIB; PACLITAXEL; PLACEBO; RAZOXANE; SORAFENIB; SUNITINIB; TELMISARTAN; TRASTUZUMAB; TROPONIN; UNINDEXED DRUG; VALSARTAN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADVERSE OUTCOME; AEROBIC EXERCISE; ANTIOXIDANT ACTIVITY; ARTICLE; BRADYCARDIA; BREAST CANCER; CANCER CHEMOTHERAPY; CARDIAC PROGENITOR CELL; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOTOXICITY; CARDIOVASCULAR MAGNETIC RESONANCE; CARDIOVASCULAR RISK; CLINICAL EFFECTIVENESS; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; CORONARY ARTERY SPASM; DIGESTIVE SYSTEM CANCER; DRUG SAFETY; ECHOCARDIOGRAPHY; ENDURANCE TRAINING; EWING SARCOMA; HEART EDEMA; HEART FAILURE; HEART INJURY; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART TRANSPLANTATION; HUMAN; HYPERTENSION; INTRACARDIAC THROMBOSIS; KIDNEY CARCINOMA; LEUKEMIA; LIVER CELL CARCINOMA; LYMPHOMA; MULTIPLE SCLEROSIS; MYOCARDITIS; NONHUMAN; OUTCOME ASSESSMENT; OVARY CANCER; QT PROLONGATION; RISK ASSESSMENT; RISK FACTOR; SARCOMA; SENSITIVITY ANALYSIS; STEM CELL; STOMACH CANCER; UROGENITAL TRACT CANCER;

EID: 84881074994     PISSN: 10928464     EISSN: 15343189     Source Type: Journal    
DOI: 10.1007/s11936-013-0248-3     Document Type: Article

References (93)

1. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010;46:765-81.
2. Suter TM, Ewer MS. Cancer drugs and the heart: importance and management. Eur Heart J. 2013;34(15):1102-11. A complete overview of pathogenesis, diagnosis and management of cardiovascular complications of both old and novel cancer drugs
3. Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol. 2009;53:2231-47.
4. Bonow RO, Bennett S, Casey Jr DE, et al. ACC/AHA clinical performance measures for adults with chronic heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Heart Failure Clinical Performance Measures): endorsed by the Heart Failure Society of America. Circulation. 2005;112:1853-87.
5. Wouters KA, Kremer LC, Miller TL, et al. Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies. Br J Haematol. 2005;131(5):561-78.
6. Silber JH, Cnaan A, Clark BJ, et al. Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. J Clin Oncol. 2004;22(5):820-8.
7. Yoon GJ, Telli ML, Kao DP, et al. Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies are clinicians responding optimally? J Am Coll Cardiol. 2010;56(20):1644-50. A very interesting insight into how cancer therapy-associated decreased left ventricular ejection fraction is managed in the real life, out of clinical trials.
8. Felker GM, Thompson RE, Hare JM, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med. 2000;342(15):1077-84.
9. Adams Jr KF, Dunlap SH, Sueta CA, et al. Relation between gender, etiology and survival in patients with symptomatic heart failure. J Am Coll Cardiol. 1996;28(7):1781-8.
10. Force T, Kolaja KL. Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes. Nat Rev Drug Discov. 2011;10:111-26.
11. Moja L, Tagliabue L, Balduzzi S, et al. Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev. 2012;4, CD006243.
12. Bowles EJ, Wellman R, Feigelson HS, et al. Pharmacovigilance Study Team. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J Natl Cancer Inst. 2012;104(17):1293-305.
13. Chen J, Long JB, Hurria A, et al. Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Coll Cardiol. 2012;60(24):2504-12 [Epub 2012 Nov 14].
14. Khouri MG, Douglas PS, Mackey JR, et al. Cancer therapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues. Circulation. 2012;126(23):2749-63. A comprehensive review about crucial topics in Cardio-Oncology research such as the definition, incidence, detection, management and clinical importance of cardiac toxicity in early breast cancer.
15. Jones RL, Ewer MS. Cardiac and cardiovascular toxicity of nonanthracycline anticancer drugs. Expert Rev Anticancer Ther. 2006;6(9):1249-69.
16. Suter TM, Ewer MS. Trastuzumab-associated cardiotoxicity. In: Ewer MS, Yeh ETH, editors. Cancer and the Heart. Hamilton, ON: BC Decker Inc; 2006. p. 67-4.
17. Jones AL, Barlow M, Barrett-Lee PJ, et al. Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring. Br J Cancer. 2009;100(5):684-92.
18. Ewer MS, Lippman SM. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol. 2005;23:2900-2.
19. Telli ML, Hunt SA, Carlson RW, et al. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J Clin Oncol. 2007;25:3525-33.
20. Steinherz LJ, Graham T, Hurwitz R, et al. Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Children's Cancer Study Group. Pediatrics. 1992;89(5 Pt 1):942-9.
21. Lipshultz SE, Sanders SP, Goorin AM, et al. Monitoring for anthracycline cardiotoxicity. Pediatrics. 1994;93(3):433-7.
22. Ritchie JL, Bateman TM, Bonow RO, et al. Guidelines for clinical use of cardiac radionuclide imaging. Report of the American College of Cardiology/American Heart Association Task Force on assessment of diagnostic and therapeutic cardiovascular procedures, in collaboration with the American Society of Nuclear Cardiology. J Am Coll Cardiol. 1995;25:521-47.
23. Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents. Incidence, treatment, and prevention. Drug Saf. 2000;22(4):263-302.
24. Meinardi MT, van der Graaf WT, van Veldhuisen DJ, et al. Detection of anthracycline-induced cardiotoxicity. Cancer Treat Rev. 1999;25(4):237-47.
25. Schwartz RG, McKenzie WB, Alexander J, et al. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy: seven-year experience using serial radionuclide angiocardiography. Am J Med. 1987;82(6):1109-18.
26. Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002;20:1215-21.
27. Geisberg CA, Sawyer DB. Mechanisms of anthracycline cardiotoxicity and strategies to decrease cardiac damage. Curr Hypertens Rep. 2010;12:404-10.
28. Sawaya H, Plana JC, Scherrer-Crosbie M. Newest echocardiographic techniques for the detection of cardiotoxicity and heart failure during chemotherapy. Heart Fail Clin. 2011;7(3):313-21. This study offers an excellent evaluation of the role of modern echocardiography in the diagnosis of cardiotoxicity.
29. Oreto L, Todaro MC, Umland MM, et al. Use of echocardiography to evaluate the cardiac effects of therapies used in cancer treatment: what do we know? J Am Soc Echocardiogr. 2012;25(11):1141-52.
30. Hundley WG, Bluemke DA, Finn JP, et al. American College of Cardiology Foundation Task Force on Expert Consensus Documents, ACCF/ACR/AHA/ NASCI/SCMR 2010 expert consensus document on cardiovascular magnetic resonance: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. J Am Coll Cardiol. 2010;55:2614-62.
31. Fallah-Rad N, Lytwyn M, Fang T, et al. Delayed contrast enhancement cardiac magnetic resonance imaging in trastuzumab induced cardiomyopathy. J Cardiovasc Magn Reson. 2008;10:5.
32. Walker J, Bhullar N, Fallah-Rad N, et al. Role of three-dimensional echocardiography in breast cancer: comparison with two-dimensional echocardiography, multiple-gated acquisition scans, and cardiac magnetic resonance imaging. J Clin Oncol. 2010;28:3429-36.
33. Armstrong GT, Plana JC, Zhang N, et al. Screening adult survivors of childhood cancer for cardiomyopathy: comparison of echocardiography and cardiac magnetic resonance imaging. J Clin Oncol. 2012;30(23):2876-84.
34. O'Brien PJ. Cardiac troponin is the most effective translational safety biomarker for myocardial injury in cardiotoxicity. Toxicology. 2008;245(3):206-18.
35. Lipshultz SE, Rifai N, Sallan SE, et al. Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. Circulation. 1997;96:2641-8.
36. Cardinale D, Sandri MT, Martinoni A, et al. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol. 2000;36:517-22.
37. Auner HW, Tinchon C, Linkesch W, et al. Prolonged monitoring of troponin T for detection of anthracycline cardiotoxicity in adults with hematological malignancies. Ann Hematol. 2003;82:218-22.
38. Lipshultz SE, Rifai N, Dalton VM, et al. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med. 2004;351:145-53.
39. Cardinale D, Sandri MT, Martinoni A, et al. Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. Ann Oncol. 2002;13:710-5.
40. Cardinale D, Sandri MT, Colombo A, et al. Prognostic value of Troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation. 2004;109:2749-54.
41. Cardinale D, Colombo A, Sandri MT, et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation. 2006;114:2474-81.
42. Cardinale D, Colombo A, Torrisi R, et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of Troponin I evaluation. J Clin Oncol. 2010;28:3910-6.
43. Lipshultz SE, Scully RE, Lipsitz SR, et al. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukemia: long-term follow-up of a prospective, randomized, multicenter trial. Lancet Oncol. 2010;11(10):950-61.
44. Lipshultz SE, Miller TL, Scully RE, et al. Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes. J Clin Oncol. 2012;30(10):1042-9.
45. Newby LK, Jesse RL, Babb JD, et al. ACCF 2012 expert consensus document on practical clinical considerations in the interpretation of troponin elevations: a report of the American College of Cardiology Foundation task force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2012;60(23):2427-63.
46. Batist G, Ramakrishnan G, Rao CS, et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol. 2001;19(5):1444-54.
47. Muggia FM, Hainsworth JD, Jeffers S, et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol. 1997;15(3):987-93.
48. Sieswerda E, Kremer LC, Caron HN, et al. The use of liposomal anthracycline analogues for childhood malignancies: a systematic review. Eur J Cancer. 2011;47(13):2000-8.
49. Legha SS, Benjamin RS, Mackay B, et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med. 1982;96(2):133-9.
50. Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979;91:710-7.
51. Nysom K, Holm K, Lipsitz SR, et al. Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia. J Clin Oncol. 1998;16(2):545-50.
52. van Dalen EC, van der Pal HJH, Caron HN, Kremer LCM. Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy. Cochrane Database Syst Rev. 2009;(4):CD005008.
53. Scott JM, Khakoo A, Mackey JR, et al. Modulation of anthracycline-induced cardiotoxicity by aerobic exercise in breast cancer: current evidence and underlying mechanisms. Circulation. 2011;124:642-50.
54. Jones L, Dolinsky VW, Haykowsky MJ, et al. Effects of aerobic training to improve cardiovascular function and prevent cardiac remodeling after cytotoxic therapy in early breast cancer. Poster presented at: 102nd Annual meeting of the American Association of Cancer Research; April 2011. Orlando, FL.
55. van Dalen EC, Caron HN, Dickinson HO, et al. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev. 2011;(6):CD003917.
56. Lipshultz SE, Rifai N, Dalton VM, et al. The effect of dexrazoxane on myocardial injury in doxorubicin- treated children with acute lymphoblastic leukemia. N Engl J Med. 2004;351(2):145-53.
57. Huh WW, Jaffe N, Durand JB, et al. Comparison of doxorubicin cardiotoxicity in pediatric sarcoma patients when given with dexrazoxane vs as continuous infusion. Pediatr Hematol Oncol. 2010;27(7):546-57.
58. Tebbi CK, London WB, Friedman D, et al. Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease. J Clin Oncol. 2007;25(5):493-500.
59. Barry EV, Vrooman LM, Dahlberg SE, et al. Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane. J Clin Oncol. 2008;26(7):1106-11.
60. Dulin B, Abraham WT. Pharmacology of carvedilol. Am J Cardiol. 2004;6:3-6.
61. Cheng J, Kamiya K, Kodama I. Carvedilol: molecular and cellular basis for its multifaceted therapeutic potential. Cardiovasc Drug Rev. 2001;19:152-71.
62. Matsui H, Morishima I, Numaguchi Y, et al. Protective effects of carvedilol against doxorubicin-induced cardiomyopathy in rats. Life Sci. 1999;65:1265-74.
63. Santos DL, Moreno AJ, Leino RL, et al. Carvedilol protects against doxorubicin-induced mitochondrial cardiomyopathy. Toxicol Appl Pharmacol. 2002;185:218-27.
64. Spallarossa P, Garibaldi S, Altieri P, et al. Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro. J Mol Cell Cardiol. 2004;37(4):837-46.
65. Kalay N, Basar E, Ozdogru I, et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol. 2006;48(11):2258-62.
66. El-Shitany NA, Tolba OA, El-Shanshory MR, et al. Protective effect of carvedilol on adriamycin-induced left ventricular dysfunction in children with acute lymphoblastic leukemia. J Card Fail. 2012;18(8):607-13.
67. Takizawa T, Arai M, Tomaru K, et al. Carvedilol effectively blocks oxidative stress-mediated downregulation of sarcoplasmic reticulum Ca2 ATPase2 gene transcription through modification of Sp1 binding. Biochem Biophys Res Commun. 2005;328:116-24.
68. Seicean S, Seicean A, Alan N, Plana JC, Budd GT, Marwick TH. Cardioprotective effect of Beta-Adrenoceptor blockade in breast cancer patients undergoing chemotherapy: a follow-up study of heart failure. Circ Heart Fail. 2013. doi: 10.1161/CIRCHEARTFAILURE.112.000055.
69. Kaya MG, Ozkan M, Gunebakmaz O, et al. Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study. Int J Cardiol. 2012. doi: 10.1016/j.ijcard.2012.06.023.
70. Nakamae H, Tsumura K, Terada Y, et al. Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone. Cancer. 2005;104(11):2492-8.
71. Cadeddu C, Piras A, Mantovani G, et al. Protective effects of the angiotensin II receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress, and early ventricular impairment. Am Heart J. 2010;160(3):487.e1-7.
72. Dessì M, Piras A, Madeddu C, et al. Long-term protective effects of the angiotensin receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress, and myocardial dysfunction. Exp Ther Med. 2011;2(5):1003-9 [Epub 2011 Jun 30].
73. Schupp N, Schmid U, Heidland A, et al. Rosuvastatin protects against oxidative stress and DNA damage in vitro via upregulation of glutathione synthesis. Atherosclerosis. 2008;199:278-87.
74. Riad A, Bien S, Westermann D, et al. Pretreatment with statin attenuates the cardiotoxicity of doxorubicin in mice. Cancer Res. 2009;69:695-9.
75. Acar Z, Kale A, Turgut M, et al. Efficiency of atorvastatin in the protection of anthracycline-induced cardiomyopathy. J Am Coll Cardiol. 2011;58:988-9.
76. Seicean S, Seicean A, Plana JC, et al. Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study. J Am Coll Cardiol. 2012;60(23):2384-90.
77. Barry E, Alvarez JA, Scully RE, et al. Anthracycline induced cardiotoxicity: course, pathophysiology, prevention and management. Expert Opin Pharmacother. 2007;8(8):1039-58.
78. Pituskin E, Haykowsky M, Mackey JR, et al. Rationale and design of the Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research Trial (MANTICORE 101-Breast): a randomized, placebo-controlled trial to determine if conventional heart failure pharmacotherapy can prevent trastuzumab-mediated left ventricular remodeling among patients with HER2+ early breast cancer using cardiac MRI. BMC Cancer. 2011;11:318.
79. Bosch X, Esteve J, Sitges M, et al. Prevention of chemotherapy-induced left ventricular dysfunction with enalapril and carvedilol: rationale and design of the OVERCOME trial. J Card Fail. 2011;17:643-8.
80. Hunt SA, Abraham WT, Chin MH, et al. American College of Cardiology Foundation; American Heart Association: 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults; a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines developed in collaboration with the International Society for Heart and Lung Transplantation. J Am Coll Cardiol. 2009;53(15):e1-90.
81. Lee AP, Ice R, Blessey R, et al. Long-term effects of physical training on coronary patients with impaired ventricular function. Circulation. 1979;60(7):1519-26.
82. van Tol BA, Huijsmans RJ, Kroon DW, et al. Effects of exercise training on cardiac performance, exercise capacity, and quality of life in patients with heart failure: a meta-analysis. Eur J Heart Fail. 2006;8(8):841-50.
83. Hughes DC, Lenihan DJ, Harrison CA, et al. Exercise intervention for cancer survivors with heart failure: two case reports. J Exerc Sci Fit. 2011;9(1):65-73.
84. Cardinale D, Colombo A, Lamantia G, et al. Anthracycline-induced cardiomyopathy. Clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol. 2010;55(3):213-20.
85. Rickard J, Kumbhani DJ, Baranowski B, et al. Usefulness of cardiac resynchronization therapy in patients with Adriamycin-induced cardiomyopathy. Am J Cardiol. 2010;105(4):522-6.
86. Oliveira GH, Hardaway BW, Kucheryavaya AY, et al. Characteristics and survival of patients with chemotherapy-induced cardiomyopathy undergoing heart transplantation. J Heart Lung Transplant. 2012;31(8):805-10.
87. Lenneman AJ, Wang L, Wigger M, et al. Heart transplant survival outcomes for adriamycin-dilated cardiomyopathy. Am J Cardiol. 2013;111(4):609-12.
88. Huang C, Zhang X, Ramil JM, et al. Juvenile exposure to anthracyclines impairs cardiac progenitor cell function and vascularization resulting in greater susceptibility to stress-induced myocardial injury in adult mice. Circulation. 2010;121(5):675-83.
89. De Angelis A, Piegari E, Cappetta D, et al. Anthracycline cardiomyopathy is mediated by depletion of the cardiac stem cell pool and is rescued by restoration of progenitor cell function. Circulation. 2010;121(2):276-92. This study offers new insights into the therapeutic approach of cardiotoxicity, suggesting that strategies that preserve or restore progenitor cell populations may have a role in the prevention or management of heart failure caused by doxorubicin.
90. Geisberg C, Pentassuglia L, Sawyer DB. Cardiac side effects of anticancer treatments: new mechanistic insights. Curr Heart Fail Rep. 2012;9(3):211-8.
91. Ewer MS, Vooletich MT, Durand JB, et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol. 2005;23(31):7820-6.
92. Romond EH, Jeong JH, Rastogi P, et al. Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor Receptor 2-Positive breast cancer. J Clin Oncol. 2012;30(31):3792-9.
93. Bird BR, Swain SM. Cardiac toxicity in breast cancer survivors: review of potential cardiac problems. Clin Cancer Res. 2008;14(1):14-24.